Fulcrum Therapeutics, Inc. expects to report cash, cash equivalents, and marketable securities of approximately $202.9 million as of December 31, 2022.
AI Assistant
FULCRUM THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.